| breast cancer - triple negative | |||
| es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) | es-BC - TNBC - NA - all population | es-BC - TNBC - NA - PDL1 positive | |
| immune chekpoint inhibitors | |||
| anti-PD-(L)1 | |||
| atezolizumab based treatment | ALEXANDRA/IMpassion-030 | ||
| atezolizumab plus carboplatin plus nab-paclitaxel | NeoTRIPaPDLA | ||
| atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | IMpassion-031 ... | IMpassion-031 ... | |
| avelumab based treatment | |||
| avelumab alone | A-Brave | ||
| durvalumab based treatment | |||
| durvalumab alone | GeparNuevo | ||
| pembrolizumab based treatment | |||
| pembrolizumab alone | KEYNOTE-522 | ||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
